ACHIEVE LIFE SCIENCES INC
NASDAQ: ACHV (Achieve Life Sciences, Inc.)
Last update: 3 hours ago6.83
-0.36 (-5.01%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Achieve Life Sciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | -1.2 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.97 |
Select this tab to load the latest available analysis.
|
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.69% |
| % Held by Institutions | 41.59% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tpg Gp A, Llc | 30 Jun 2026 | 6,877,580 |
| Venbio Partners Llc | 30 Jun 2026 | 5,914,720 |
| Propel Bio Management, Llc | 30 Jun 2026 | 4,034,018 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |